Drugs / IBI303
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02893254 | Sep 2016 → Jan 2018 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02893254 ↗ |
| Action | Inhibit | “IBI303 is a monoclonal antibody against TNFα” PMID 38229357 ↗ Aug 2019 |
| Modality | Monoclonal antibody | “IBI303 is a monoclonal antibody against TNFα” PMID 38229357 ↗ Aug 2019 |
| Route | Subcutaneous | “IBI303 40mg administered subcutaneously every other week” NCT02893254 ↗ |
| Target | TNF | “IBI303 is a monoclonal antibody against TNFα” PMID 38229357 ↗ Aug 2019 |